KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $4.2 million.

  • Neogenomics' Change in Receivables rose 57376.13% to $4.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.2 million, marking a year-over-year decrease of 6801.12%. This contributed to the annual value of $6.2 million for FY2025, which is 6801.12% down from last year.
  • Per Neogenomics' latest filing, its Change in Receivables stood at $4.2 million for Q4 2025, which was up 57376.13% from $2.4 million recorded in Q3 2025.
  • Neogenomics' 5-year Change in Receivables high stood at $9.1 million for Q1 2024, and its period low was -$3.9 million during Q1 2021.
  • Over the past 5 years, Neogenomics' median Change in Receivables value was $1.5 million (recorded in 2022), while the average stood at $2.5 million.
  • As far as peak fluctuations go, Neogenomics' Change in Receivables tumbled by 16852.5% in 2021, and later skyrocketed by 127145.83% in 2023.
  • Over the past 5 years, Neogenomics' Change in Receivables (Quarter) stood at $7.2 million in 2021, then increased by 7.69% to $7.7 million in 2022, then crashed by 118.3% to -$1.4 million in 2023, then soared by 37.11% to -$888000.0 in 2024, then surged by 573.76% to $4.2 million in 2025.
  • Its Change in Receivables stands at $4.2 million for Q4 2025, versus $2.4 million for Q3 2025 and -$1.1 million for Q2 2025.